Answers are grounded in this paper and cite their sources.
Demonstrates selective biosynthesis of monoterpene esters in engineered microbes, suggesting new strategies for biomanufacturing.
Reconstructing the precise biosynthesis of structurally complex natural esters, such as monoterpene esters, in engineered microbes remains a major challenge, owing to the limited repertoire of highly selective alcohol acyltransferases and the lack of compatible pathway modularity. Here, we establish a dual-substrate microbial platform to profile the activities of alcohol acyltransferase (AAT) to synthesize three distinct classes of monoterpene esters: monoterpenyl esters, monoterpenoate esters, and monoterpenyl monoterpenoate esters, enabling access to both natural and non-natural monoterpene ester biosynthetic pathways. Through structure-guided critical residue engineering and dual-substrate molar ratio tuning, we achieve selective biosynthesis of >C2 acyl-CoA-derived monoterpene esters, despite competing intracellular acetyl-CoA. Coculture engineering further redistributed metabolic fluxes between acyl-CoA and alcohol precursors, yielding 11.50 g/L linalyl acetate and 3.16 g/L geranyl butyrate in 1-L bioreactor. This study expands the biosynthetic space of monoterpene esters and provides a versatile strategy to control AAT selectivity, offering a plug-and-play, scalable framework for ester biomanufacturing. Microbial biosynthesis of monoterpene esters remains a major challenge due to the limited repertoire of highly selective alcohol acyltransferases (AATs). Here the authors discovered and engineered AATs for various monoterpene esters using a dual-substrate microbial platform.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: